The Experts below are selected from a list of 4203 Experts worldwide ranked by ideXlab platform

Roman S Pavelyev - One of the best experts on this subject based on the ideXlab platform.

Svetlana A Lisovskaya - One of the best experts on this subject based on the ideXlab platform.

Herman Goossens - One of the best experts on this subject based on the ideXlab platform.

  • outpatient systemic Antimycotic and antifungal use in europe new outcome measure provides new insight
    International Journal of Antimicrobial Agents, 2013
    Co-Authors: Niels Adriaenssens, Samuel Coenen, Ann Versporten, Herman Goossens
    Abstract:

    To broaden our understanding of outpatient systemic Antimycotic and antifungal use in Europe, use data in defined daily doses (DDD) were complemented with data in packages and the results were compared. Within the European Surveillance of Antimicrobial Consumption project and using the Anatomical Therapeutic Chemical (ATC) classification, data on outpatient use of all 14 Antimycotics (12) and antifungals (2) for systemic use (ATC J02 and D01B), aggregated at the level of the active substance, were collected for 2009. Their use was expressed in DDD per 1000 inhabitants per day (DID) and in packages per 1000 inhabitants per day (PID) (WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD version 2011). In total, 24 countries delivered data in DID; 13 countries also delivered data in PID. In DID, Belgium had the highest (3.24 DID) and Romania the lowest (0.38 DID) total outpatient Antimycotic and antifungal use. In PID, Greece had the highest (0.44 PID) and Sweden the lowest (0.08 PID) use. In DID, terbinafine was the most used substance in 19/24 countries (10/13 countries providing DID and PID data). In PID, fluconazole was the most used substance in all 13 countries. Combining DID and PID data substantially improved the interpretation of total outpatient Antimycotic and antifungal use in Europe, and both outcome measures should be used for surveillance of these compounds. High use of fluconazole in PID might be more relevant for surveillance of antimicrobial consumption in relation to resistance than high use of terbinafine in DID.

  • european surveillance of antimicrobial consumption esac outpatient systemic Antimycotic and antifungal use in europe
    Journal of Antimicrobial Chemotherapy, 2010
    Co-Authors: Niels Adriaenssens, Samuel Coenen, Arno Muller, Vanessa Vankerckhoven, Herman Goossens
    Abstract:

    Results: In 20 European countries (data for Cyprus and Estonia include hospital use), total outpatient systemic Antimycotic and antifungal use varied by a factor of 6.7 between the country with the highest (3.03 DID in Belgium) and the country with the lowest (0.45 in Croatia) use. Terbinafine, ketoconazole, itraconazole and fluconazole represented .94% of the total outpatient Antimycotic and antifungal use in all countries. Terbinafine use represented .50% of the total systemic Antimycotic and antifungal use in 16 out of 20 countries (not in Croatia, Italy, Luxembourg and Bulgaria). Conclusions: We present for the first time a standardized and validated data set of outpatient systemic Antimycotic and antifungal use in Europe. Our study demonstrates a variation of Antimycotic and antifungal use in Europe, as striking as that of antibiotic use. The ESAC data facilitate the auditing of Antimycotic and antifungal prescribing, and the evaluation of the implementation of guidelines and public health policies to promote their judicious use.

Rusalia M Vafina - One of the best experts on this subject based on the ideXlab platform.

Alexey B Dobrynin - One of the best experts on this subject based on the ideXlab platform.